Circulating Tumor DNA in Breast Cancer: A Liquid Biopsy Revolution for Non-Invasive Genomic Profiling and Clinical Decision-Making Authors: Emmanuel Ifeanyi Obeagu, Chukwuma J Okafor Published: 2026 ABSTRACT AbstractBreast cancer remains the most frequently diagnosed cancer and a leading cause of cancer-related mortality among women worldwide, underscoring the need for accurate, minimally invasive biomarkers to support precision oncology. Conventional tissue biopsy remains the standard for molecular characterization but is limited by its invasiveness, inability to capture spatial and temporal tumor heterogeneity, and challenges in serial monitoring. Circulating tumor DNA (ctDNA), a tumor-derived fraction of cell-free DNA, has emerged as a promising liquid biopsy biomarker capable of providing real-time genomic information throughout disease progression. This narrative review examines recent advances in ctDNA biology, analytical technologies, clinical applications, current limitations, and future directions in breast cancer management. A structured literature search of PubMed/MEDLINE, Scopus, Embase, Web of Science, and Google Scholar identified relevant English-language publications from 2015 to 2026. Current evidence indicates that highly sensitive platforms, including digital PCR, BEAMing, and next-generation sequencing, can detect clinically actionable alterations in genes such as PIK3CA, ESR1, TP53, ERBB2, AKT1, and BRCA1/2. ctDNA has demonstrated particular utility in identifying minimal residual disease, monitoring therapeutic response, detecting emerging resistance mechanisms, and guiding targeted treatment selection in advanced breast cancer. However, applications in early cancer detection, population screening, and artificial intelligence-assisted clinical decision-making remain investigational. Widespread clinical implementation is constrained by low ctDNA abundance in early-stage disease, analytical variability, limited assay standardization, and cost considerations. Continued technological innovation, prospective multicenter validation, standardized testing protocols, and evidence-based clinical guidelines are essential to fully integrate ctDNA into routine precision breast cancer care.Keywords: circulating tumor DNA, liquid biopsy, breast cancer, precision oncology, genomic profiling Introduction Breast cancer remains the most commonly diagnosed malignancy in women worldwide and a leading cause of cancer-related mortality. Significant advances in early detection, imaging, and systemic therapies have affected outcomes; however, traditional diagnostic and monitoring approaches are limited by inherent constraints. Genomic characterization of tumors by tissue biopsy remains the gold standard, but only provides a static snapshot of a single region in the tumor, often fails to account for spatial heterogeneity or the dynamic evolution of the disease. Repeated biopsies are invasive, costly and not always feasible, especially in the metastatic setting. These challenges have resulted in a need for minimally invasive approaches to provide real-time insight into tumor biology.1-3 Liquid biopsy, and in particular the analysis of circulating tumor DNA (ctDNA), has emerged as a promising solution. Apoptosis, necrosis or active secretion by tumor cells release ctDNA, which is a fragment of DNA into the blood stream. These fragments are enriched with tumor-specific genomic and epigenetic alterations such as point mutations, copy number variations, structural rearrangements, and methylation patterns. Importantly, ctDNA reflects systemic tumor burden, including primary and metastatic sites, and the clonal evolution over time, providing a dynamic view of tumor biology that tissue biopsies cannot. 4 The clinical applications of ctDNA in breast cancer are multiple. ctDNA may allow for wide genomic profiling for therapy selection, early detection of malignancy, monitoring of minimal residual disease (MRD), real-time evaluation of treatment response, and early detection of emerging resistance mechanisms. Technological advances, including digital droplet PCR, next-generation sequencing, ultra-sensitive fragmentomic and methylation-based assays, and computational algorithms, have improved the sensitivity and specificity of ctDNA detection, enabling its incorporation into clinical workflows. 5 Despite its promise, ctDNA-based liquid biopsy faces challenges. Early-stage tumors and biologically low-shedding subtypes may produce ctDNA at levels below current detection thresholds. Variability in assay methods and the lack of standardized clinical thresholds complicate interpretation, and cost and accessibility remain barriers in some healthcare settings. Nonetheless, ctDNA represents a transformative biomarker that can bridge the gap between tumor biology and precision oncology. 6 This narrative review explores the biological underpinnings of ctDNA, technological advancements in its detection, and emerging clinical applications in breast cancer. By synthesizing current evidence, the review highlights how ctDNA has the potential to redefine genomic characterization, disease monitoring, and personalized treatment strategies, paving the way for a new era of minimally invasive, real-time precision oncology. Aim This narrative review aims to provide an overview of the current evidence on circulating tumor DNA (ctDNA) as a liquid biopsy tool for breast cancer genomic characterization. The review specifically aims to explore the biology of ctDNA, the technological advancements that have made detection possible, and its clinical utility for tumor profiling, early detection, minimal residual disease monitoring, real-time assessment of treatment response and detection of emerging therapy resistance. This review aims to highlight the potential of ctDNA as a non-invasive, precision oncology tool, able to guide individualized breast cancer management integrating preclinical insights, translational studies and emerging clinical evidence. Methods This article was conducted as a narrative review to provide a comprehensive and critical synthesis of the current evidence on the role of circulating tumor DNA (ctDNA) in breast cancer, with particular emphasis on non-invasive genomic profiling, liquid biopsy technologies, clinical applications, and future perspectives in precision oncology. Unlike a systematic review, this narrative review was designed to integrate contemporary evidence, summarize emerging concepts, and critically discuss ongoing advances and challenges without performing a formal quantitative evidence synthesis or risk-of-bias assessment. A structured literature search was performed using PubMed/MEDLINE, Scopus, Embase, Web of Science, and Google Scholar to identify relevant studies published between January 2015 and June 2026. The search strategy combined Medical Subject Headings (MeSH) and free-text terms, including “breast cancer,” “circulating tumor DNA,” “ctDNA,” “cell-free DNA,” “liquid biopsy,” “genomic profiling,” “minimal residual disease,” “treatment monitoring,” “precision oncology,” “digital PCR,” “droplet digital PCR,” “BEAMing,” “next-generation sequencing,” “artificial intelligence,” and “liquid biopsy guidelines.” Boolean operators (“AND” and “OR”) were used to optimize the search and retrieve relevant publications. Eligible publications included original research articles, prospective and retrospective cohort studies, randomized clinical trials, translational studies, systematic reviews, meta-analyses, narrative reviews, consensus statements, and international clinical practice guidelines published in English. Particular emphasis was placed on landmark studies and recent high-quality evidence evaluating ctDNA for molecular profiling, minimal residual disease detection, therapeutic response monitoring, identification of resistance mechanisms, prognostic assessment, and precision treatment selection in breast cancer. Publications focusing exclusively on non-breast malignancies, conference abstracts lacking sufficient methodological detail, editorials, commentaries, duplicate publications, and non-English articles were excluded. Additional relevant studies were identified through manual screening of the reference lists of selected articles. The retrieved literature was critically reviewed and narratively synthesized into thematic sections addressing ctDNA biology, analytical technologies, clinically actionable genomic alterations, current clinical applications, international guideline recommendations, implementation challenges, artificial intelligence integration, and future research priorities. Because this study is a narrative review, formal study selection by multiple independent reviewers, methodological quality assessment, risk-of-bias evaluation, meta-analysis, and PRISMA reporting were not performed. This approach was considered appropriate for providing an up-to-date, clinically oriented overview of this rapidly evolving field while acknowledging the inherent limitations of narrative evidence synthesis. The graphical abstract was generated with BioRender software assistance based on current evidence in precision oncology and reviewed for accuracy by the authors. Biological Basis of ctDNA ctDNA represents a small fraction of the total cell-free DNA (cfDNA) present in the bloodstream, originating specifically from malignant cells. Its release into circulation is primarily mediated by tumor cell apoptosis and necrosis, although emerging evidence suggests that active secretion via extracellular vesicles or tumor-derived exosomes also contributes. These biological processes generate DNA fragments that carry the molecular hallmarks of the tumor, including somatic mutations, copy number alterations, structural rearrangements, and epigenetic modifications such as aberrant methylation. 7 A defining feature of ctDNA is its fragment size. Tumor-derived DNA fragments are typically shorter than cfDNA from normal cells, reflecting distinct chromatin organization and nuclease activity during cell death. This fragmentation pattern not only enhances the detectability of ctDNA but also serves as a biomarker in its own right, as fragmentomic signatures can distinguish malignant DNA from normal cfDNA. Beyond size, ctDNA carries tumor-specific genetic alterations that mirror the heterogeneity of the primary tumor and metastatic sites, providing a comprehensive snapshot of tumor biology at a given time. 8 The quantity of ctDNA in circulation is influenced by multiple factors, including tumor burden, location, vascularity, cellular turnover, and breast cancer subtype. Highly proliferative and genomically unstable tumors, such as triple-negative or HER2-positive breast cancers, often release higher levels of ctDNA, whereas low-shedding tumors or early-stage lesions may produce amounts that challenge current detection technologies.9-11 Critically, ctDNA captures temporal heterogeneity as tumors evolve under selective pressures from therapy or the immune system. As resistant clones emerge, their distinct mutations appear in circulation, offering real-time insights into tumor adaptation and progression. This dynamic property enables ctDNA to function not only as a diagnostic biomarker but also as a surveillance tool for minimal residual disease (MRD), early relapse detection, and monitoring of therapy resistance (Table 1).12,13 Table 1.Biological Basis of ctDNABiological aspectDescriptionOrigin/MechanismKey featuresClinical relevance in breast cancerSource of ctDNATumor-derived fragmented DNA circulating in bloodReleased via apoptosis, necrosis, and active secretion from tumor cellsShort DNA fragments (∼150–200 bp), low abundance in plasmaEnables non-invasive access to tumor genetic materialTumor SheddingVariable release of DNA depending on tumor activityHigher in rapidly proliferating, hypoxic, or necrotic tumorsCorrelates with tumor burden and vascularityHigher levels associated with advanced disease and metastasisFragmentation PatternCharacteristic DNA fragmentation profilesEndonuclease cleavage during cell death processesFragment size distribution differs from normal cfDNAHelps distinguish tumor-derived DNA from normal cfDNAGenetic ContentTumor-specific molecular alterationsSomatic mutations, CNVs, rearrangementsIncludes PIK3CA, TP53, ESR1, HER2 alterationsSupports targeted therapy selection and resistance monitoringClearance DynamicsRemoval of ctDNA from circulationHepatic, renal clearance, and nuclease degradationShort half-life (∼15 minutes to a few hours)Enables real-time monitoring of tumor dynamicsHeterogeneity RepresentationReflects multiple tumor clonesDNA shed from primary tumor and metastatic sitesCaptures spatial and temporal heterogeneityImproves detection of clonal evolution and resistanceInteraction with cfDNAMixed with normal circulating cell-free DNADerived from hematopoietic and normal tissue cellsTumor fraction often <1% in early diseaseRequires highly sensitive detection methodsEpigenetic SignalsDNA methylation and chromatin-associated patternsTumor-specific epigenetic reprogrammingMethylation signatures can be tumor-type specificEnhances early detection and tumor classification Biological Basis of ctDNA Technological Innovations in ctDNA Detection The clinical utility of ctDNA depends on the accurate detection and quantification of tumor-specific fragments in a vast excess of normal cell-free DNA. The past decade has seen technological advances that have translated into remarkable improvements in the sensitivity, specificity, and clinical utility of ctDNA assays, allowing the evolution of ctDNA from a research tool to a practical tool in the precision oncology armamentarium of breast cancer. 14 Digital droplet PCR (ddPCR) represents one of the first and more widely used innovations. By partitioning DNA samples into thousands to millions of microdroplets, ddPCR allows for the absolute quantification of specific mutations at variant allele frequencies as low as 0.01%. This high sensitivity makes it particularly useful for tracking known mutations in patient-specific contexts, such as monitoring MRD or detecting emerging resistance mutations like ESR1 and PIK3CA. ddPCR is rapid, cost-effective, and relatively straightforward to implement, providing a practical option for targeted mutation analysis.15,16 Next-generation sequencing (NGS) technologies have expanded ctDNA analysis from targeted mutation detection to comprehensive genomic profiling. Deep sequencing approaches, including hybrid-capture and amplicon-based panels, allow simultaneous interrogation of multiple genes, enabling the identification of point mutations, copy number variations, structural rearrangements, and other genomic alterations. Integration of unique molecular identifiers (UMIs) and error-correction algorithms enhances the accuracy of NGS, allowing detection of low-frequency variants that would otherwise be masked by technical noise. 17 Ultra-sensitive sequencing platforms such as CAPP-Seq (cancer personalized profiling by deep sequencing), Safe-SeqS, and Phased Variant Sequencing have further increased the detection threshold, making it possible to identify ctDNA fragments present at parts-per-million concentrations. These approaches combine molecular barcoding, error suppression, and deep coverage, allowing clinicians to detect residual disease and track clonal evolution even in patients with minimal tumor burden. 18 Beyond sequence-based approaches, fragmentomics and epigenetic profiling have emerged as complementary strategies. Tumor-derived ctDNA exhibits distinctive fragmentation patterns and nucleosomal positioning, which can be leveraged to enhance detection sensitivity. Similarly, aberrant DNA methylation—often an early and tissue-specific event in breast tumorigenesis—can be detected in ctDNA using bisulfite sequencing, targeted methylation panels, or cfMeDIP-seq, providing a sensitive marker for early-stage disease and low-shedding tumors. 19 The integration of AI and machine learning (ML) into ctDNA analysis represents a transformative advance. AI-driven algorithms can synthesize complex datasets, incorporating mutation profiles, methylation patterns, fragmentomics, and copy number alterations to improve classification accuracy and predict clinical outcomes. This computational layer enhances the interpretability and clinical utility of ctDNA, facilitating precision-guided decision-making (Table 2). 20 Table 2.Technological Innovations in ctDNA DetectionTechnologyPrincipleKey strengthsLimitationsApplication in breast cancerDigital PCR (dPCR)Partitioning of DNA into thousands of reactions for absolute quantification of target mutationsExtremely high sensitivity, rapid turnaround, cost-effective for known mutationsLimited multiplexing and genomic breadthDetection of hotspot mutations (e.g., PIK3CA, ESR1), treatment monitoringDroplet Digital PCR (ddPCR)Emulsification of DNA into nanoliter droplets for single-molecule analysisUltra-sensitive, precise quantification of low-frequency variantsRequires prior knowledge of mutationsMRD detection and longitudinal response trackingTargeted Next-Generation Sequencing (tNGS)Deep sequencing of predefined gene panelsBalanced sensitivity and genomic coverage, clinically actionable outputsRestricted to selected genesComprehensive profiling of actionable mutations (HER2, BRCA1/2, TP53)Hybrid-Capture NGSEnrichment of genomic regions using hybrid probes prior to sequencingHigh accuracy, broad variant detection (SNVs, CNVs, indels)Higher cost, longer turnaround timeBroad molecular profiling and resistance mutation detectionAmplicon-Based NGSPCR amplification of target regions prior to sequencingRequires low DNA input, fast and scalablePCR bias, limited structural variant detectionRapid mutation screening in metastatic diseaseWhole Exome Sequencing (WES)Sequencing of all protein-coding regions of genomeHigh discovery potential, broad mutation landscapeLow sensitivity for low ctDNA fractionsResearch use for tumor evolution and heterogeneity studiesWhole Genome Sequencing (WGS)Sequencing of entire genome including non-coding regionsComprehensive structural variant detectionHigh cost, low ctDNA sensitivity requirementsStructural variation and chromosomal instability analysisMethylation-Based AssaysDetection of tumor-specific DNA methylation patternsHigh specificity for tumor origin, useful in early detectionComplex data interpretationEarly detection and tumor classificationError-Correction Sequencing (UMI-based NGS)Use of unique molecular identifiers to correct sequencing errorsUltra-high accuracy, detects ultra-low frequency variantsComputationally intensiveMRD detection and early relapse predictionFragmentomics AnalysisAnalysis of cfDNA fragment size and patternsNon-mutational signal detection, improves sensitivityStill emerging, lacks standardizationEarly detection and tumor signal enrichmentMachine Learning–Enhanced ctDNA AnalysisAI-driven interpretation of sequencing and longitudinal dataImproved predictive accuracy, integrates multi-omics dataRequires large datasets and validationPrediction of recurrence and therapy response Technological Innovations in ctDNA Detection Clinical Applications in Genomic Characterization ctDNA offers a transformative approach to genomic characterization in breast cancer, enabling comprehensive, real-time insights into tumor biology that complement or, in certain contexts, replace tissue biopsy. Its clinical applications span multiple dimensions, including tumor profiling, early detection, MRD monitoring, treatment response assessment, and detection of emerging therapy resistance (Table 3). 12 Table 3.Clinical Applications in Genomic Characterization of Breast Cancer Using ctDNAClinical applicationDescriptionctDNA roleKey genomic features detectedClinical impactEarly Diagnosis (Investigational)Identification of breast cancer at asymptomatic or early symptomatic stagesDetects tumor-derived mutations and methylation signatures in plasmaLow-frequency SNVs, methylation patterns, fragmentomics signalsPotential for earlier intervention and improved survival outcomesMolecular SubtypingClassification of breast cancer into molecular subtypesProvides genomic and epigenomic profiles reflective of tumor biologyESR1, ERBB2 (HER2), PIK3CA, TP53 alterationsGuides selection of endocrine, HER2-targeted, or chemotherapy regimensPrognostic StratificationEstimation of disease outcome and recurrence riskQuantifies ctDNA burden and mutation loadVariant allele frequency (VAF), clonal architectureIdentifies high-risk patients requiring intensified therapyMinimal Residual Disease (MRD) DetectionIdentification of residual tumor cells after curative treatmentDetects ultra-low ctDNA levels post-surgery or chemotherapyPatient-specific mutations, tumor-informed panelsPredicts relapse months before imaging, informs adjuvant therapyTreatment Response MonitoringReal-time evaluation of therapeutic effectivenessSerial quantification of ctDNA levels during therapyDynamic changes in mutation burden and ctDNA concentrationEnables early therapy modification or continuation decisionsDetection of Acquired ResistanceIdentification of therapy-induced genetic evolutionTracks emergence of resistance mutationsESR1 mutations, PI3K pathway alterations, HER2 mutationsSupports switching or escalation of targeted therapiesMetastatic Disease ProfilingGenomic characterization of advanced diseaseCaptures heterogeneity across metastatic sitesMulti-clonal mutations, copy number variationsEnables non-invasive biopsy alternative for treatment planningTherapy Selection (Precision Oncology)Matching targeted therapy to genomic alterationsIdentifies actionable mutations for drug targetingPIK3CA, BRCA1/2, AKT1, HER2 amplificationImproves response rates through personalized therapyLongitudinal Disease SurveillanceContinuous monitoring of disease evolution over timeRepeated sampling enables tracking of clonal dynamicsEmerging mutations and clonal expansion patternsEarly detection of progression or relapseClinical Trial StratificationSelection of patients for targeted therapy trialsIdentifies biomarker-positive patient subgroupsActionable genomic alterations and resistance markersEnhances trial efficiency and therapeutic discovery Clinical Applications in Genomic Characterization of Breast Cancer Using ctDNA Comprehensive Tumor Profiling ctDNA facilitates systemic profiling of tumor-specific genetic alterations, capturing mutations, copy number variations, structural rearrangements, and epigenetic modifications. Unlike tissue biopsies, which are confined to a single tumor region, ctDNA reflects heterogeneity across primary and metastatic sites, allowing a holistic view of tumor genomics. This capability is particularly valuable for identifying actionable mutations in genes such as PIK3CA, ESR1, HER2, and BRCA1/2, which inform targeted therapy selection. Serial ctDNA monitoring further enables detection of clonal evolution and emerging resistance mechanisms, guiding personalized treatment adjustments over time. 21 Early Detection and Screening ctDNA has shown promise as a biomarker for early breast cancer detection, particularly in high-risk populations such as BRCA mutation carriers or individuals with a strong family history. Tumor-specific mutations, aberrant methylation patterns, and fragmentomic signatures can be detected in circulation months before radiologic evidence emerges. These molecular insights offer potential for earlier intervention and more individualized screening strategies, although sensitivity remains a challenge in low-shedding, early-stage tumors. 22 Minimal Residual Disease (MRD) Monitoring Post-treatment ctDNA detection serves as a robust marker for MRD, providing an early signal of residual disease that is often undetectable by imaging or conventional laboratory tests. Patients with detectable ctDNA after surgery, neoadjuvant therapy, or adjuvant therapy are at significantly higher risk of recurrence. Personalized, tumor-informed ctDNA assays allow highly sensitive monitoring, enabling timely intervention and tailored follow-up strategies to improve outcomes. 23 Real-Time Monitoring of Treatment Response Dynamic changes in ctDNA levels closely mirror tumor burden and therapeutic efficacy. Early declines in ctDNA during systemic therapy indicate effective treatment, while persistent or rising levels suggest inadequate response or emerging resistance. This real-time monitoring is particularly useful in assessing neoadjuvant chemotherapy response, endocrine therapy efficacy, targeted therapy outcomes, and immunotherapy effects, allowing clinicians to adapt treatment strategies promptly. 24 Detection of Therapy Resistance and Tumor Evolution ctDNA captures the molecular evolution of tumors under therapeutic pressure, providing early warning of resistance. For example, ESR1 mutations emerging during aromatase inhibitor therapy, HER2 pathway alterations during targeted treatment, and BRCA reversion mutations under PARP inhibitor therapy can be identified through ctDNA months before clinical progression. Detecting these changes in real time enables timely modification of therapy, potentially delaying relapse and improving long-term outcomes.22,25,26 Clinical Decision-Making and Precision Oncology The incorporation of ctDNA into clinical decision-making represents a major advancement in the transition from traditional population-based oncology to precision oncology. In breast cancer management, therapeutic decisions have historically relied on histopathological features and single-time-point tissue-based genomic profiling. While informative, these approaches fail to account for spatial and temporal tumor heterogeneity, which is a key driver of treatment failure and disease recurrence. ctDNA addresses this limitation by providing a real-time, minimally invasive molecular snapshot of tumor dynamics throughout the disease course.10,22 In precision oncology, ctDNA enables the stratification of patients based on actionable genomic alterations that can directly inform targeted therapy selection. For example, detection of PIK3CA mutations may guide the use of PI3K inhibitors, while identification of ESR1 mutations in hormone receptor-positive metastatic breast cancer can inform resistance to aromatase inhibitors and prompt alternative endocrine strategies. Similarly, HER2 amplification detected in ctDNA can support anti-HER2 therapy decisions, particularly in cases where tissue biopsy is unavailable or inconclusive. This molecular adaptability allows clinicians to refine treatment regimens in response to evolving tumor biology rather than relying solely on baseline diagnostic data.22,27 A particularly impactful application of ctDNA is in the monitoring of treatment response and early detection of therapeutic resistance. Serial ctDNA measurements provide quantitative and qualitative insights into tumor burden dynamics. A declining ctDNA level during therapy generally correlates with favorable response, whereas stable or rising levels may indicate subclinical progression before radiologic confirmation. This early warning capability supports timely therapeutic modification, thereby reducing exposure to ineffective treatments and minimizing unnecessary toxicity.28,29 ctDNA also plays a critical role in the detection of MRD following surgery or systemic therapy. The presence of detectable ctDNA after curative-intent treatment is strongly associated with imminent relapse, often preceding clinical or imaging-based recurrence by several months. This has significant implications for adjuvant treatment planning, as MRD-positive patients may benefit from treatment intensification or inclusion in clinical trials, while MRD-negative patients could potentially avoid overtreatment.30,31 In metastatic breast cancer, ctDNA-guided profiling provides a non-invasive alternative when tumor tissue is difficult to obtain or insufficient for molecular testing. It allows repeated sampling over time, capturing clonal evolution under therapeutic pressure and revealing emergent resistance mechanisms. This longitudinal monitoring capability is particularly valuable in heavily pretreated patients, where tumor heterogeneity is pronounced and static biopsies are least informative (Figure 1).32,33 Overview of Clinical Decision-Making and Precision Oncology to optimize personalized treatment strategies and patient outcomes. Image created by authors using BioRender software and scientific workflow adapted 34 Discussion Circulating tumor DNA (ctDNA) has emerged as one of the most promising liquid biopsy biomarkers in breast cancer, offering a minimally invasive approach for dynamic genomic profiling that complements conventional tissue biopsy. Unlike tissue sampling, which provides only a single spatial and temporal representation of the tumor, ctDNA reflects the evolving genomic landscape of both primary and metastatic lesions through serial blood sampling. This capability enables longitudinal monitoring of tumor evolution, clonal heterogeneity, treatment response, and the emergence of resistance mechanisms, making ctDNA an important component of precision oncology. The expanding evidence reviewed in this manuscript supports the growing clinical relevance of ctDNA while highlighting important limitations that currently restrict its widespread implementation. One of the most established clinical applications of ctDNA is the detection of actionable genomic alterations in metastatic breast cancer. Highly sensitive analytical platforms, including droplet digital PCR (ddPCR), BEAMing, and next-generation sequencing (NGS), can identify mutations in clinically relevant genes such as PIK3CA, ESR1, ERBB2, AKT1, TP53, and BRCA1/2. Detection of these alterations facilitates personalized therapeutic selection, including PI3K inhibitors for patients with PIK3CA-mutated disease and endocrine treatment modification in patients harboring acquired ESR1 mutations. Compared with repeated tissue biopsy, ctDNA provides a safer, less invasive alternative that allows continuous genomic surveillance throughout disease progression.35,36 Another important application is the detection of minimal residual disease (MRD) following curative-intent treatment. Multiple prospective studies have demonstrated that persistent postoperative ctDNA is strongly associated with an increased risk of recurrence and frequently precedes radiological or clinical relapse by several months. This lead time creates opportunities for earlier intervention and more individualized surveillance strategies. However, although MRD detection represents one of the most promising applications of ctDNA, its routine incorporation into standard clinical practice remains under evaluation. Further prospective randomized studies are needed to determine whether ctDNA-guided therapeutic interventions improve disease-free survival and overall survival. Serial ctDNA monitoring also provides valuable information regarding treatment response and disease progression. Declining ctDNA concentrations during systemic therapy generally correlate with favorable treatment response, whereas increasing ctDNA levels may indicate therapeutic resistance or impending disease progression before conventional imaging demonstrates measurable changes. Such dynamic monitoring may facilitate earlier treatment modification and improve individualized patient management. Nevertheless, standardized thresholds for clinically meaningful changes in ctDNA levels have not yet been universally established, limiting the consistency of interpretation across different studies and clinical settings.37,38 Technical and analytical variability also remains an important concern. Numerous ctDNA detection platforms are currently available, each differing in sequencing depth, analytical sensitivity, specificity, error correction strategies, and mutation coverage. Pre-analytical variables—including blood collection tubes, sample processing time, plasma separation protocols, DNA extraction methods, and storage conditions—may substantially influence assay performance and reproducibility. Furthermore, clonal hematopoiesis of indeterminate potential can generate somatic mutations unrelated to malignancy, potentially leading to false-positive results if appropriate confirmatory analyses are not performed. These challenges underscore the need for standardized laboratory procedures, quality assurance programs, and harmonized reporting criteria before ctDNA testing can be universally adopted. The role of ctDNA in early breast cancer detection and population screening also requires careful consideration. Although technological advances have substantially improved analytical sensitivity, ctDNA concentrations remain extremely low in many patients with localized disease, reducing detection accuracy and increasing the likelihood of false-negative findings. Consequently, current evidence does not support ctDNA as a standalone screening tool for asymptomatic populations. Future improvements in ultra-sensitive sequencing technologies, methylation profiling, fragmentomics, and integrated multi-analyte liquid biopsy platforms may enhance early detection performance, but these approaches remain investigational and require validation in large prospective screening studies.39,40 Artificial intelligence (AI) represents another rapidly evolving area with considerable potential to enhance ctDNA interpretation. Machine learning algorithms may improve variant classification, distinguish clinically relevant mutations from background biological noise, predict therapeutic response, and integrate ctDNA findings with radiological imaging, digital pathology, proteomics, transcriptomics, and electronic health records. However, most AI-assisted applications remain at the developmental or validation stage and challenges related to external validation, algorithm transparency, dataset heterogeneity, regulatory oversight, and clinical implementation must be addressed before routine adoption. 41 Accordingly; AI should currently be viewed as a complementary investigational tool rather than an established component of ctDNA-guided clinical decision-making. Current international guidelines similarly reflect a cautious but encouraging perspective. Organizations including ASCO, ESMO, and NCCN recognize the growing utility of ctDNA for identifying actionable genomic alterations in advanced breast cancer and acknowledge its potential role in treatment selection. However, they also emphasize that applications such as MRD-guided treatment escalation, recurrence surveillance, and early cancer detection require additional prospective validation before routine implementation.42,43 This distinction between evidence-supported and investigational applications is essential to ensure appropriate clinical use and avoid premature adoption. Future research should focus on large multicenter prospective clinical trials evaluating the impact of ctDNA-guided treatment strategies on patient outcomes. Harmonization of analytical methods, establishment of standardized reporting frameworks, definition of clinically meaningful ctDNA thresholds, and comprehensive cost-effectiveness analyses will be critical for broader implementation. In addition, integrating ctDNA with complementary biomarkers, including circulating tumor cells, circulating RNA, extracellular vesicles, proteomics, metabolomics, and radiomics, may improve diagnostic accuracy and predictive performance through multimodal precision oncology approaches.44,45 Current International Guideline Recommendations Regarding Circulating Tumor DNA (ctDNA) in Breast Cancer46-49 International oncology guidelines increasingly recognize the clinical value of circulating tumor DNA (ctDNA) as a complementary tool for precision oncology in breast cancer. However, they also emphasize that its routine clinical use should currently be limited to evidence-supported indications while several promising applications remain investigational. The American Society of Clinical Oncology (ASCO) acknowledges ctDNA as a valuable liquid biopsy modality for identifying actionable genomic alterations in patients with advanced or metastatic breast cancer, particularly when tumor tissue is unavailable, insufficient, or difficult to obtain. ASCO recognizes the utility of ctDNA for detecting mutations such as PIK3CA, which may guide treatment with PI3K inhibitors, and ESR1 mutations associated with endocrine resistance. Nevertheless, ASCO advises that a negative ctDNA result should not exclude the presence of clinically relevant mutations because of potential false-negative findings resulting from low tumor DNA shedding. Consequently, tissue-based genomic testing remains the preferred reference standard whenever feasible (Table 4). Table 4.Summary of Current International Guideline Recommendations for ctDNA in Breast CancerOrganizationCurrent recommendationClinical statusASCOSupports ctDNA for detection of actionable mutations (e.g., PIK3CA, ESR1) in advanced breast cancer when tissue is unavailable or inadequate; negative plasma results should be interpreted cautiously.Recommended in selected clinical scenarios.NCCNAccepts plasma ctDNA as an alternative for genomic profiling in metastatic or recurrent breast cancer when tissue biopsy is not feasible; recommends tissue confirmation when appropriate.Recommended in selected patients.ESMORecommends validated ctDNA assays for molecular profiling and monitoring resistance mechanisms in advanced disease; emphasizes assay validation and quality assurance.Recommended with validated platforms.ESMO Precision Medicine Working GroupRecommends standardized analytical procedures, harmonized reporting, and careful interpretation of ctDNA results, including consideration of CHIP-related variants.Supports clinical implementation with rigorous quality standards.Consensus Across GuidelinesMRD monitoring, early detection, population screening, recurrence surveillance, and AI-assisted clinical decision-making remain investigational pending prospective validation.Not recommended for routine clinical practice outside research settings. Summary of Current International Guideline Recommendations for ctDNA in Breast Cancer Similarly, the National Comprehensive Cancer Network (NCCN) recommends the use of plasma ctDNA testing as an acceptable alternative for comprehensive genomic profiling in selected patients with recurrent or metastatic breast cancer when tissue biopsy is not feasible or when additional tissue cannot be safely obtained. The NCCN supports the identification of actionable biomarkers to guide targeted therapies but advises confirmatory tissue testing whenever clinically appropriate, particularly when plasma testing is negative despite strong clinical suspicion of actionable molecular alterations. The European Society for Medical Oncology (ESMO) recommends ctDNA testing for molecular characterization of advanced cancers when validated assays are available and clinically actionable genomic alterations are anticipated. ESMO recognizes ctDNA as a useful tool for detecting emerging resistance mechanisms, monitoring clonal evolution, and facilitating precision treatment selection in metastatic breast cancer. However, the Society emphasizes that standardized laboratory procedures, validated analytical platforms, and robust quality assurance measures are essential to ensure reliable clinical interpretation. The ESMO Precision Medicine Working Group further recommends that ctDNA assays used in clinical practice should undergo rigorous analytical and clinical validation before implementation. The Working Group highlights the importance of standardized pre-analytical procedures, quality control, harmonized reporting standards, and careful interpretation of low-frequency variants. It also cautions clinicians regarding false-positive findings caused by clonal hematopoiesis of indeterminate potential (CHIP), which may confound plasma-based mutation analysis. Despite these encouraging recommendations, all major international guidelines consistently state that several ctDNA applications remain investigational. These include population-based cancer screening, early breast cancer detection, routine surveillance following curative treatment, minimal residual disease (MRD)-guided therapeutic escalation or de-escalation, and artificial intelligence-assisted ctDNA interpretation. Current evidence suggests considerable promise in these areas; however, prospective randomized clinical trials demonstrating improvements in patient outcomes are still required before routine implementation can be recommended. Overall, current international guidelines support ctDNA as a complementary biomarker for genomic profiling and therapeutic decision-making in selected patients with advanced breast cancer, while emphasizing that conventional tissue biopsy remains the diagnostic gold standard. Future updates to these recommendations are expected as evidence from ongoing prospective trials evaluating ctDNA-guided treatment strategies, MRD monitoring, and multimodal precision oncology continues to emerge. Future Perspectives The future of ctDNA in the management of breast cancer is closely aligned with the broader evolution of precision oncology, multi-omics integration, and computational medicine. As technological sensitivity improves and analytical frameworks mature, ctDNA is expected to transition from a supportive biomarker to a central pillar of cancer diagnosis, monitoring, and therapeutic decision-making. A major direction of development lies in the enhancement of analytical sensitivity and specificity, particularly for early-stage breast cancer and MRD detection. Current limitations in detecting extremely low variant allele fractions are being addressed through ultra-deep sequencing, improved error-correction strategies such as unique molecular identifiers (UMIs), and novel signal amplification approaches. These innovations are expected to significantly reduce false negatives and expand the clinical utility of ctDNA to earlier disease stages, including screening and post-treatment surveillance in curative settings. 10 Another emerging frontier is the integration of ctDNA with complementary circulating biomarkers, including CTCs, extracellular vesicles (exosomes), circulating RNA, and proteomic signatures. A multi-analyte liquid biopsy framework offers a more comprehensive representation of tumor biology by combining genomic, transcriptomic, and proteomic data. This integrative approach is likely to improve diagnostic accuracy, enhance prognostic stratification, and provide deeper insights into tumor heterogeneity and evolutionary dynamics. 35 AI and machine learning are also expected to play a transformative role in ctDNA interpretation. Large-scale longitudinal ctDNA datasets can be leveraged to develop predictive models for disease recurrence, treatment response, and the evolution of resistance. These computational tools may enable real-time clinical decision support systems that dynamically recommend therapy adjustments based on evolving molecular profiles. Such systems would mark a shift toward fully adaptive oncology, where treatment is continuously optimized based on molecular feedback loops.36-38 In the context of clinical application, ctDNA is likely to expand into population-level screening and early detection strategies. Although still in the investigational stage, highly sensitive assays capable of detecting tumor-derived DNA in asymptomatic individuals could complement or augment existing imaging-based screening modalities. This would be particularly valuable in high-risk populations, such as individuals with BRCA1/2 mutations or strong family histories of breast cancer.39,40 Another important future direction involves ctDNA-guided adaptive clinical trials. In these frameworks, treatment allocation and modification are driven by real-time molecular data rather than fixed protocols. Such trial designs improve efficiency, reduce patient exposure to ineffective therapies, and accelerate the evaluation of targeted agents. This approach aligns with the broader shift toward biomarker-driven trial designs in oncology (Table 5).41,42 Table 5.Future Perspectives of ctDNA in Breast CancerFuture directionDescriptionExpected advancementClinical/Research impactUltra-sensitive early detectionImprovement in detection of very low ctDNA fractions in early-stage diseaseEnhanced sequencing depth, error-correction (UMIs), novel signal amplificationEnables screening and diagnosis before clinical/radiologic detectionMinimal residual disease (MRD) expansionBroader adoption of ctDNA for post-treatment surveillanceTumor-informed assays and standardized MRD platformsEarlier relapse detection and improved adjuvant therapy selectionMulti-omics liquid biopsy integrationCombination of ctDNA with CTCs, exosomes, RNA, and proteomicsHolistic tumor profiling across molecular layersImproved diagnostic accuracy and tumor characterizationAI-driven predictive oncologyUse of machine learning for ctDNA interpretationPredictive models for recurrence, resistance, and survivalReal-time clinical decision support systemsctDNA-guided adaptive therapyTreatment adjustments based on serial ctDNA monitoringDynamic, response-driven treatment algorithmsImproved outcomes through real-time therapy optimizationEarly cancer screening applicationsPopulation-level detection of breast cancer using ctDNA signaturesHighly sensitive methylation and fragmentomics assaysPotential shift toward non-invasive routine screeningStandardization and harmonizationDevelopment of global protocols for ctDNA testingUniform sample processing, reporting, and interpretationImproved reproducibility and clinical adoptionCost reduction and accessibilityLower-cost sequencing and point-of-care platformsScalable technologies for low-resource settingsBroader global equity in precision oncologyctDNA-guided clinical trialsBiomarker-driven adaptive trial designsReal-time stratification and treatment allocationFaster drug development and improved trial efficiencyIntegration into clinical guidelinesFormal incorporation into oncology practice standardsEvidence-based consensus from large-scale trialsRoutine use in breast cancer management pathways Future Perspectives of ctDNA in Breast Cancer Conclusion ctDNA has emerged as a transformative liquid biopsy biomarker that is reshaping the landscape of precision oncology in breast cancer by enabling minimally invasive, real-time genomic profiling throughout the disease continuum. Current evidence supports its clinical utility in identifying actionable genomic alterations, monitoring treatment response, detecting emerging therapeutic resistance, and assessing minimal residual disease, particularly in patients with advanced breast cancer. These capabilities offer significant advantages over conventional tissue biopsy by facilitating longitudinal assessment of tumor evolution and intratumoral heterogeneity. Low ctDNA abundance in early-stage disease, biological variability in tumor DNA shedding, differences in analytical platforms, lack of standardized pre-analytical and analytical protocols, and uncertainties regarding clinically meaningful thresholds continue to limit widespread implementation. In addition, applications such as early cancer detection, population screening, minimal residual disease-guided therapeutic intervention, and artificial intelligence-assisted clinical decision-making remain investigational and require robust prospective validation before they can be incorporated into standard care. Future progress will depend on large multicenter clinical trials, international assay harmonization, standardized reporting frameworks, cost-effectiveness analyses, and the development of evidence-based clinical guidelines. Integration of ctDNA with complementary biomarkers, multi-omics technologies, advanced imaging, and artificial intelligence may further enhance diagnostic accuracy, prognostic assessment, and personalized therapeutic decision-making. As these scientific and clinical challenges are addressed, ctDNA is poised to become an integral component of precision breast cancer management, supporting more individualized treatment strategies, earlier detection of disease recurrence, and improved patient outcomes while complementing, rather than replacing, conventional tissue-based diagnostics. Abbreviations deoxyribonucleic acid circulating tumor DNA Polymerase Chain Reaction Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha Estrogen Receptor alpha Tumor Protein p53 Epidermal Growth Factor Receptor 2 Breast Cancer Associated Gene 1 and 2 minimal residual disease cell-free DNA Copy number variants Human Epidermal growth factor Receptor 2 Digital droplet PCR Next-generation sequencing unique molecular identifiers Cancer personalized profiling by deep sequencing cell-free methylated DNA immunoprecipitation and high-throughput sequencing Digital PCR Targeted Next-Generation Sequencing Whole Exome Sequencing Whole Genome Sequencing Phosphoinositide 3-kinase American Society of Clinical Oncology European Society for Medical Oncology National Comprehensive Cancer Network Author Contributions: Conceptualization: Emmanuel Ifeanyi Obeagu, Methodology: Chukwuma J. Okafor, Emmanuel Ifeanyi Obeagu. Writing Original Draft: Emmanuel Ifeanyi Obeagu. Investigation: Emmanuel Ifeanyi Obeagu, Chukwuma J. Okafor. Formal Analysis: Chukwuma J. Okafor. Writing Review and Editing: Chukwuma J. Okafor. Funding: The authors received no financial support for the research, authorship, and/or publication of this article. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Transparency Statement: All authors have read and approved the final version of the manuscript. The authors have full access to all data and takes complete responsibility for the integrity and accuracy of the analysis. ORCID iDs Emmanuel Ifeanyi Obeagu https://orcid.org/0000-0002-4538-0161 Chukwuma J. Okafor https://orcid.org/0000-0002-2815-1439 Data Availability Statement The authors have nothing to report.* References Associated Data Data Availability Statement The authors have nothing to report.*